A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty

Journal of Thrombosis and Thrombolysis

Volumn 31, Issue 2, 2011, Pages 233-234

  Silvano, M ^a   Zambon, C F ^a   De Rosa, G ^a   Plebani, M ^a   Pengo, V ^a   Napodano, M ^a   Padrini, R ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DOCETAXEL; PRASUGREL; TROPONIN I;

ADULT; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; CASE REPORT; CORONARY STENT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELUTING STENT; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE NECROSIS; HUMAN; MALE; NOTE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; ST SEGMENT ELEVATION; STENT THROMBOSIS; THORAX PAIN; THROMBOCYTE AGGREGATION;

ANGIOPLASTY, BALLOON, CORONARY; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE; DRUG-ELUTING STENTS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TAXOIDS; THIOPHENES; THROMBOSIS; TICLOPIDINE;

EID: 79951726925     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0533-x     Document Type: Note

References (13)

1. KJ Ellis GA Stouffer HL McLeod CR Lee 2009 Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations Pharmacogenomics 10 1799 1817 1:CAS:528:DC%2BD1MXhtlOiu77J 10.2217/pgs.09.143 19891556
2. JL Mega SL Close SD Wiviott L Shen RD Hockett JT Brandt JR Walker EM Antman W Macias E Braunwald MS Sabatine 2009 Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 354 362 1:CAS:528:DC%2BD1MXhtVSlsbs%3D 10.1056/NEJMoa0809171 19106084
3. A Harmsze JW van Werkum HJ Bouman HJ Ruven NJ Breet JM Ten Berg CM Hackeng MM Tjoeng OH Klungel A de Boer VH Deneer 2010 Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation Pharmacogenet Genomics 20 18 25 1:CAS:528:DC%2BD1MXhsFKgurfL 10.1097/FPC.0b013e328333dafe 19934793
4. WC Lau PA Gurbel PB Watkins CJ Neer AS Hopp DG Carville KE Guyer AR Tait ER Bates 2004 Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 166 171 1:CAS:528:DC%2BD2cXis1Citw%3D%3D 10.1161/01.CIR.0000112378.09325.F9 14707025 (Pubitemid 38114134)
5. PM Ho TM Maddox L Wang SD Fihn RL Jesse ED Peterson JS Rumsfeld 2009 Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 937 944 1:CAS:528:DC%2BD1MXivFejt7g%3D 10.1001/jama.2009.261 19258584
6. TA Clarke LA Waskell 2003 The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin Drug Metab Dispos 31 53 59 1:CAS:528:DC%2BD3sXhtV2msA%3D%3D 10.1124/dmd.31.1.53 12485953 (Pubitemid 36735258)
7. AM Gori R Marcucci R Paniccia B Giusti S Fedi E Antonucci P Buonamici D Antoniucci GF Gensini R Abbate 2008 Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function Thromb Haemost 100 1136 1145 1:CAS:528:DC%2BD1MXptVygsw%3D%3D 19132241
8. JD Balian N Sukhova JW Harris J Hewett L Pickle JA Goldstein RL Woosley DA Flockhart 1995 The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study Clin Pharmacol Ther 57 662 669 1:CAS:528:DyaK2MXntValtrg%3D 10.1016/0009-9236(95)90229-5 7781266
9. Y Böttiger 2006 Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4 Eur J Clin Pharmacol 62 621 625 10.1007/s00228-006-0156-5 16791583 (Pubitemid 44127990)
10. JL Mega SL Close SD Wiviott L Shen RD Hockett JT Brandt JR Walker EM Antman WL Macias E Braunwald MS Sabatine 2009 Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2553 2560 1:CAS:528:DC%2BD1MXmtVKntrs%3D 10.1161/CIRCULATIONAHA.109.851949 19414633
11. P Fontana A Dupont S Gandrille C Bachelot-Loza JL Reny M Aiach P Gaussem 2003 Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects Circulation 108 989 995 1:CAS:528:DC%2BD3sXmsVOrs7c%3D 10.1161/01.CIR.0000085073.69189.88 12912815 (Pubitemid 37048230)
12. DJ Angiolillo A Fernandez-Ortiz E Bernardo C Ramírez U Cavallari E Trabetti M Sabaté P Jimenez-Quevedo R Hernández R Moreno J Escaned F Alfonso C Bañuelos MA Costa TA Bass PF Pignatti C Macaya 2005 Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease Thromb Res 116 491 497 1:CAS:528:DC%2BD2MXhtVegtLbM 10.1016/j.thromres.2005.03.001 16181985 (Pubitemid 41330814)
13. P Eshtehardi M Eslami DA Moayed 2008 Simultaneous subacute coronary drug-eluting stent thrombosis in two different vessels of a patient with factor V Leiden mutation J Cardiovasc Med 9 410 413 10.2459/JCM.0b013e3282eee98b (Pubitemid 351374275)